


# Journal Pre-proof

Tranexamic acid in cutaneous oncology and cosmetic surgery: a comprehensive narrative review

Pablo Balado-Simó MD Sofía Gomez-Martinez MD Daniel Morgado-Carrasco MD



PII: S0001-7310(25)00754-9

DOI: <https://doi.org/doi:10.1016/j.ad.2025.104485>

Reference: AD 104485

To appear in: *Actas dermosifiliograficas*

Received Date: 4 May 2025

Accepted Date: 13 July 2025

Please cite this article as: Balado-Simó P, Gomez-Martinez S, Morgado-Carrasco D, Tranexamic acid in cutaneous oncology and cosmetic surgery: a comprehensive narrative review, *Actas dermosifiliograficas* (2025), doi: <https://doi.org/10.1016/j.ad.2025.104485>

This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability. This version will undergo additional copyediting, typesetting and review before it is published in its final form. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Please note that Elsevier's sharing policy for the Published Journal Article applies to this version, see: <https://www.elsevier.com/about/policies-and-standards/sharing#4-published-journal-article>. Please also note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 AEDV. Published by Elsevier España, S.L.U.

## Sección: Dermatología Práctica

### Tranexamic acid in cutaneous oncology and cosmetic surgery: a comprehensive narrative review

#### Authors and affiliations:

Pablo Balado-Simó, MD<sup>1</sup>; Sofía Gomez-Martinez, MD<sup>1</sup>; and Daniel Morgado-Carrasco, MD<sup>1,2\*</sup>

<sup>1</sup>Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain

<sup>2</sup>Servicio de Dermatología, Hospital de Figueres, Fundació Salut Empordà, Figueres, Girona, Spain

#### \*Corresponding author

Daniel Morgado-Carrasco

E-mail address: morgadodaniel8@gmail.com

#### Abstract

Tranexamic acid (TXA) is a synthetic lysine analog with antifibrinolytic properties used to reduce bleeding during various surgical procedures. In dermatologic surgery, it is often applied topically (soaked gauze), subcutaneously (intralesional with local anesthesia), and intravenously. We conducted a narrative review on the utility of TXA in dermatologic surgery, both oncologic and aesthetic. Therefore, we conducted a literature search across PubMed and Google Scholar during March 2025, including retrospective and prospective studies, and systematic reviews. We eventually found multiple randomized clinical trials demonstrating a reduction in intra- and postoperative bleeding, ecchymosis, and minor hematomas, especially in Mohs surgery, blepharoplasty, and facial rhytidectomy (facelift), and reduced surgical duration during blepharoplasty and rhytidectomy. The safety profile of TXA is highly favorable, with no observed increase in thromboembolic events. However, optimal dosing and routes of administration have yet to be established.

**Keywords:** tranexamic acid; Mohs surgery; skin cancer; blepharoplasty; facelift; bleeding; dermatology.

## I. INTRODUCTION

Tranexamic acid (TXA) is a synthetic analog of lysine with an antifibrinolytic effect. It blocks the binding sites of plasminogen to fibrin, preventing its conversion to plasmin and stabilizing the fibrin mesh, thereby reducing bleeding (Figure 1)<sup>1</sup>. It has been successfully used to reduce hemorrhagic complications in general surgery and gynecology, among other surgical specialties<sup>2,3</sup>. Recent studies show that it can reduce bleeding in Mohs micrographic surgery (MMS)<sup>4,5</sup>, in blepharoplasties<sup>6,7</sup>, and in facial rhytidectomy (facelift)<sup>8,9</sup>. TXA has been used in gauze impregnated with the drug<sup>10</sup>, subcutaneously (intralesionally)—most often mixed with local anesthetics<sup>4</sup>—or intravenously prior to surgery<sup>11</sup>. Below, we present a review on the effectiveness and safety of TXA in oncologic and aesthetic dermatologic surgery.

## II. MATERIALS AND METHODS

We conducted a narrative review in March 2025 through searches across Medline and Google Scholar using the keywords: “*tranexamic acid*,” “*tranexamic*,” “*surgery*,” “*skin cancer*,” “*dermatology*,” “*bleeding*,” “*Mohs surgery*,” “*blepharoplasty*,” “*rhytidectomy*,” “*facelift*,” “*aesthetic surgery*,” “*plastic surgery*.” Articles in Spanish and English were included, encompassing retrospective and prospective studies (> 10 patients), clinical trials (CTs), meta-analyses, systematic reviews (SRs), and ongoing CTs listed in *clinicaltrials.gov*. Articles were screened by title and abstract and selected according to relevance. All 3 authors participated in the search and selection process.

### III. RESULTS

#### III.a Effectiveness in Oncologic Dermatologic Surgery

We found 8 articles on the use of TXA in oncologic dermatologic surgery for skin cancer<sup>2,3,8-13</sup> (Table 1), including three randomized controlled trials (RCTs) and 1 S<sup>5</sup>. Most of these studies demonstrated that TXA is safe and effective as a hemostatic adjuvant in MMS<sup>5</sup>.

##### *Gauze impregnated with tranexamic acid*

A double-blind RCT<sup>10</sup> compared topical TXA 25 mg/mL applied with a dressing to saline in 124 patients undergoing MMS. No TXA-treated patients experienced active bleeding within 48 hours postoperatively vs 6 from the control group ( $p = 0.028$ ). Due to the small sample size, the subgroup of anticoagulated patients could not be analyzed. Another RCT ( $n = 54$ )<sup>16</sup> showed reduced bleeding ( $11.42 \text{ mL} \pm 6.40$  vs  $17.60 \text{ mL} \pm 6.22$ ,  $p = 0.001$ ) and a lower rate of ecchymosis ( $3.8\%$  vs  $82.1\%$ ;  $p < 0.001$ ) with 3% topical TXA vs control. Patients on anticoagulant or antiplatelet therapy were excluded. Finally, a case-control study ( $n = 40$ )<sup>12</sup> observed a lower ratio between the blood-stain area on the gauze (applied over the tumor bed) and the size of the surgical defect in the treated group ( $1:1.47$  vs  $1:3.37$ ;  $p < 0.001$ ).

##### *Subcutaneous (intralesional) injection of tranexamic acid*

A double-blind RCT<sup>4</sup> with 127 patients undergoing MMS compared subcutaneous (intralesional) injection of TXA 100 mg/mL mixed with local anesthesia vs anesthesia alone. The ratio between the blood-stain area and the defect size was significantly lower with TXA ( $1:1.77$  vs  $1:2.49$ ;  $p < 0.001$ ). Additionally, anticoagulated patients exhibited less bleeding (mean difference [MD]  $-0.83$ ; 95% confidence interval [CI]:  $-1.20$  to  $-0.46$ ;  $p < 0.001$ ) and better subjective hemostasis assessments ( $p = 0.043$  overall;  $p = 0.001$  in anticoagulated patients).

A large retrospective study<sup>15</sup> ( $n = 5,327$ ) in patients with MMS showed a significant 25% relative risk (RR) reduction in bleeding ( $0.75$  [ $0.57-0.99$ ]) and a 51% reduction for bleeding requiring medical attention ( $0.49$  [ $0.31-0.77$ ]) in the TXA-treated group ( $n = 2,818$ ). This reduction was also significant among patients using antiplatelet or direct-acting oral anticoagulants, but not in anticoagulated patients overall. No increased rate of thromboembolic events was observed. Another retrospective study<sup>14</sup> ( $n = 115$ ) on MMS with interpolated flaps (e.g., paramedian forehead or melolabial) found only 1 bleed in the TXA group vs 27 in the non-TXA group ( $4.8\%$  vs  $28.7\%$ ;  $p < 0.01$ ).

Currently, an RCT (NCT06057675) is recruiting to evaluate subcutaneous TXA 100 mg/mL vs local anesthesia alone for nasal reconstruction after MMS.

#### III.b Effectiveness in Blepharoplasty (Table 2)

Ahmed et al.<sup>17</sup> (2024) reviewed meta-analyses and SRs on TXA use in rhinoplasty, septorhinoplasty, and blepharoplasty. For the latter, they included 6 SRs<sup>18-22</sup>—the most recent from 2023<sup>22</sup>—covering 44 to 243 patients (each SR included 1–5 studies). Three SRs showed lower bleeding volume with TXA vs placebo, with similar results across topical, intralesional, and systemic routes. Five SRs reported reduced drainage volume and a trend toward less ecchymosis and edema. No significant differences were found in postoperative hematoma rates. One meta-analysis<sup>22</sup> including 6 studies found a significant reduction in

hemorrhage risk ( $-1.05$ ; 95%CI,  $-1.72$  to  $-0.38$ ), though only 1 study<sup>6</sup> focused on blepharoplasty.

Recently, new RCTs with larger sample sizes, not included in these systematic reviews, have been published:

### ***Subcutaneous (intralesional) injection of tranexamic acid***

A double-blind RCT<sup>7</sup> ( $n = 130$ ) in which each eyelid received TXA 50 mg/mL (with lidocaine, bupivacaine, and adrenaline) on one side and no TXA on the other, found less ecchymosis in the treated side on day 0 (score 1.39 vs 1.64;  $p = 0.001$ ) and day 7 (score 1.23 vs 1.50;  $p < 0.001$ ), and lower patient-reported bruising at day 7 (25% vs 69%;  $p < 0.001$ ). Another smaller RCT<sup>23</sup> ( $n = 15$ ) using a similar design showed greater bleeding with TXA, though ecchymosis did not differ at 7 days.

### ***IV infusion of tranexamic acid***

A recent RCT<sup>24</sup> ( $n = 325$ ) compared 1 g IV TXA 10 minutes before surgery vs none, observing lower ecchymosis scores at day 8 ( $4.1 \pm 1.6$  vs  $5.8 \pm 1.7$ ;  $p < 0.0001$ ). Another RCT<sup>25</sup> ( $n = 106$ ) compared IV TXA (1 g 20 min pre-op) and subcutaneous TXA (50 mg/mL intralesional) vs control (lidocaine with adrenaline), finding lower ecchymosis and edema scores in both TXA groups.

## **III.c Effectiveness in Facial Rhytidectomy (Facelift) (Table 3)**

Al-Hashimi et al.<sup>8</sup> (2023) published an SR including 3 studies<sup>11,26,27</sup> with different administration routes, concluding that due to heterogeneity in dose and technique, the efficacy of TXA in rhytidectomy remained debatable. More recently, Alenazi et al.<sup>9</sup> (2024) published an SR of 7 studies (388 patients) with various TXA routes, concluding that TXA significantly reduced postoperative drainage and minor hematomas without increasing major complications. We analyze the main studies below:

### ***Topical tranexamic acid***

Serrano Reyes et al.<sup>27</sup> prospectively compared intraoperative irrigation with 2.5% TXA in 15 patients vs no irrigation in 15 controls, finding reduced drainage within the first 24 hours (10 mL vs 35 mL;  $p = 0.009$ ). A retrospective study ( $n = 57$ )<sup>28</sup> used TXA-soaked compresses placed beneath the skin flap while the contralateral side was being dissected, repeating the process on the opposite side while the first was being closed. Only 1 hematoma requiring drainage was observed, with no relevant complications.

### ***Subcutaneous (intralesional) injection of tranexamic acid***

Klimczak et al.<sup>29</sup> published in 2024 a double-blind randomized clinical trial in which 70 patients received subcutaneous TXA 1 mg/mL mixed with local anesthetic on one side of the face, while the other side received anesthetic alone. One week after the procedure, the area of ecchymosis was significantly smaller on the TXA-treated side ( $20.8 \pm 10.2$  vs  $28.5 \pm 12.1$ ;  $p < 0.001$ ). Another similar RCT ( $n = 74$ )<sup>30</sup> showed a reduction in surgical time and blood loss with TXA, although the difference did not reach statistical significance. Regarding dosage,

Kochuba et al.<sup>31</sup> compared TXA 1 mg/mL vs 2 mg/mL on opposite sides of the face in an RCT (n = 39) and found no differences in time to hemostasis or postoperative drainage.

Regarding comparative studies between administration routes, Pou et al.<sup>32</sup> conducted a retrospective study (n = 175) evaluating three groups: no TXA, topical TXA 25 mg/mL, and subcutaneous/intralesional TXA 5 mg/mL. Both TXA administration routes reduced drainage and ecchymosis, with the subcutaneous route being superior in reducing surgical time, seroma formation, and blood loss. Other retrospective studies and case series have reported similar results.<sup>26, 33</sup> Currently, an ongoing RCT (NCT06345833) is comparing subcutaneous (intralesional) TXA 1%, topical TXA 3%, and their combination.

#### ***IV infusion of tranexamic acid***

A double-blind RCT (n = 44)<sup>11</sup> using TXA 1 g IV administered before and 4 hours after incision vs placebo found a significant reduction in ecchymosis rated by the surgeon ( $1.33 \pm 0.32$  vs  $1.63 \pm 0.55$ ;  $p = 0.03$ ) and fewer serosanguineous collections (1 vs 5;  $p < 0.01$ ). A retrospective study analyzed 100 patients treated with TXA 10 mg/mL IV plus 10 mL/g subcutaneous (intralesional) TXA vs a no-TXA group, showing less intraoperative bleeding, shorter surgical time, and reduced ecchymosis, edema, and drain removal time in the TXA-treated groups.<sup>34</sup>

Regarding comparative studies, a very recent double-blind RCT (n = 60)<sup>35</sup> compared TXA 1 g IV vs TXA 150 mg subcutaneous (intralesional) and reported a shorter time to drain removal only in the IV group (1.16 vs 2.04 days;  $p = 0.04$ ).

#### **III.d. Effectiveness in other dermatologic surgical procedures**

A retrospective case–control study<sup>13</sup> with 40 patients undergoing lipoma excision reported a significantly lower ecchymosis score at the first postoperative visit in the TXA-treated group (which received 500 mg orally every 12 hours within the first 5 days after surgery) vs controls. No differences were observed in postoperative edema.

#### **III.e. Safety profile of tranexamic acid**

The use of TXA in dermatologic surgery shows a very low rate of adverse events (AEs).<sup>5, 18</sup> Some patients may experience dizziness, headache, nausea, or abdominal pain. No increase in the risk of cardiopulmonary or cerebrovascular thromboembolic events has been observed in association with its use.<sup>17</sup>

### **IV. DISCUSSION**

Evidence on the effectiveness and safety of TXA in surgery is well established<sup>36</sup>. Clinical trials have shown reduced mortality from postpartum and major traumatic bleeding without increasing thromboembolic risk<sup>37, 38</sup>. In a survey of 502 U.S. plastic surgeons, 90% reported using TXA in aesthetic surgery (83.6% in facelifts), and 92% had not observed AEs<sup>39</sup>. However, its application in dermatologic surgery is only recently being explored<sup>5</sup>. Major hemorrhages requiring medical attention after dermatologic surgery are exceedingly rare, and severe events with long-term complications are even less common—making TXA use in this context debatable. Most TXA studies in dermatologic surgery involve cosmetic procedures, where reducing ecchymosis is more relevant given patient expectations.

In blepharoplasty, TXA may reduce intraoperative bleeding and postoperative ecchymosis, among other parameters.<sup>18–22</sup> Regarding facelift (rhytidectomy), the most widely used routes of administration are IV and subcutaneous (intralesional). Its main benefits include a reduction in surgical time, intraoperative bleeding, ecchymosis, and minor hematomas. However, it does not appear to reduce larger hematomas.<sup>9</sup>

In dermatologic oncologic surgery (such as Mohs micrographic surgery, MMS), TXA may decrease the incidence of ecchymosis, hematoma, and postoperative edema, improve overall patient satisfaction, and reduce by half the rate of postoperative bleeding events requiring medical attention.<sup>15</sup> This may be particularly relevant in patients using antithrombotic agents or direct oral anticoagulants (DOACs).<sup>15</sup> In addition, in more complex surgical procedures, TXA may reduce surgical time (although no studies have specifically evaluated this in MMS). Despite several RCTs supporting the efficacy of TXA,<sup>4, 10, 16</sup> there are currently no standardized guidelines or protocols for its use in dermatologic oncologic surgery—likely due to the recency of studies and the heterogeneity in administration routes and dosages reported in the literature.<sup>5</sup> Indeed, no studies have evaluated IV TXA use in dermatologic oncologic surgery, unlike in blepharoplasty and facelift. Furthermore, although there are at least 3 RCTs published on dermatologic oncologic surgery, 5 in blepharoplasty, and 5 in facelift (Tables 1, 2, and 3), methodologies are often heterogeneous, as are the outcome measures used to assess drug effectiveness, and in several studies, it remains uncertain whether the reduction in bleeding is clinically meaningful. In our clinical practice, we usually employ TXA in patients at high risk of bleeding (due to either patient characteristics or surgical complexity), using it by soaking gauze pads, injecting intralesionally into the surgical bed, or as part of tumescent anesthesia (Table 4).

Regarding its use in anticoagulated patients or those taking antiplatelet agents, there is evidence supporting the usefulness of TXA.<sup>40–42</sup> In MMS, it appears to reduce hemorrhagic risk, as demonstrated in subgroup analyses from several studies.<sup>4, 15</sup> In the case of blepharoplasty and facelift, such patients are usually excluded from trials, so no evidence is currently available.

Concerning its safety profile, TXA is well tolerated across all routes of administration (topical, intralesional, and systemic), with no observed increase in serious adverse events such as cardiopulmonary or cerebrovascular thromboembolism.<sup>43</sup>

With regard to cost, TXA is inexpensive in the hospital setting within the Spanish National Health System—in our center, a 500 mg vial costs €0.32—thus, cost would not be a limiting factor for its use.

## V. LIMITATIONS

This review is limited by its narrative design—it is neither a systematic review nor a meta-analysis. Few studies evaluate TXA use in oncologic dermatologic surgery, and no consensus exists on optimal route or dosage. Similarly, there is no universally accepted method to assess surgical bleeding or postoperative hemorrhage.

## VI. CONCLUSIONS

TXA is a safe drug for dermatologic surgery, with no observed increase in cardioembolic risk. It may reduce intra- and postoperative bleeding complications and surgical time in complex procedures such as facial rhytidectomy and blepharoplasty. However, optimal dosage, route, and patient selection remain undefined, given the low baseline hemorrhagic

complication rate in dermatologic surgery. Further studies are needed to evaluate its use in both MMS and aesthetic procedures, directly comparing TXA dosages and administration routes.

## XI. REFERENCES


1. Cai J, Ribkoff J, Olson S, Raghunathan V, Al-Samkari H, DeLoughery TG, et al. The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. *Eur J Haematol.* 2020;104:79-87.
2. Roberts I. Tranexamic acid in trauma: how should we use it? *J Thromb Haemost JTH.* 2015;13 Suppl 1:S195-199.
3. Zakhari A, Sanders AP, Solnik MJ. Tranexamic acid in gynecologic surgery. *Curr Med Res Opin.* 2020;36:513-20.
4. Zilinsky I, Barazani TB, Visentin D, Ahuja K, Martinowitz U, Haik J. Subcutaneous Injection of Tranexamic Acid to Reduce Bleeding During Dermatologic Surgery: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. *Dermatol Surg Off Publ Am Soc Dermatol Surg Al.* 2019;45:759-67.
5. Kumar EA, Morris LM, Michalski-McNeely BM. Tranexamic Acid in Mohs Micrographic Surgery: A Systematic Review. *Dermatol Surg Off Publ Am Soc Dermatol Surg Al.* 2025;51:17-9.
6. Sagiv O, Rosenfeld E, Kalderon E, Barazani TB, Zloto O, Martinowitz U, et al. Subcutaneous tranexamic acid in upper eyelid blepharoplasty: a prospective randomized pilot study. *Can J Ophthalmol J Can Ophtalmol.* 2018;53:600-4.
7. Paramo R, Cheng T, Malik A, Fan J, Barmettler A. Effect of Tranexamic Acid on Intra- and Postoperative Bleeding in Eyelid Surgery: A Prospective, Randomized, Multicenter, Double-Masked, Control Trial. *Ophthal Plast Reconstr Surg.* 2024;40:331-5.
8. Al-Hashimi M, Kaur P, Charles W, Bhasta M, Nahai F, Khajuria A. A Systematic Review of the Efficacy and Safety of Tranexamic Acid in Facelift Surgery. *Aesthet Surg J.* 2023;43:1211-8.
9. Alenazi AS, Obeid AA, Alderaywsh A, Alrabiah A, Alkaoud O, Ashoor M, et al. Impact of Tranexamic Acid on Bleeding Outcomes and Complication Rates in Facelift: A Systematic Review and Meta-analysis. *Aesthet Surg J.* 2024;44:NP749-61.
10. Castillo B, Anokhin A, Golda N. Randomized study on the topical application of tranexamic acid to the wound bed of granulating defects for hemostasis in the setting of Mohs micrographic surgery. *J Am Acad Dermatol.* 2023;88:1134-5.
11. Cohen JC, Glasgold RA, Alloju LM, Glasgold MJ. Effects of Intravenous Tranexamic Acid During Rhytidectomy: A Randomized, Controlled, Double-Blind Pilot Study. *Aesthet Surg J.* 2021;41:155-60.
12. Zilinsky I, Barazani TB, Shenkman B, Weisman O, Farber N, Martinowitz U. Topical Hemostatic-Anesthetic Solution to Reduce Bleeding During Mohs Micrographic Surgery: A Case Control Study. *J Drugs Dermatol JDD.* 2016;15:851-5.
13. Choi Y-J, Park HJ, Lee HJ, Lee G-Y, Kim W-S. Effect of Tranexamic Acid Administration on Postoperative Ecchymosis and Edema in Excision of Lipomas. *Dermatol Surg Off Publ Am Soc Dermatol Surg Al.* 2021;47:345-8.
14. Freeman SC, Heath MS, Neill B, Morris C, Lucero OM, Yu W, et al. Tranexamic Acid Prevention of Hemorrhagic Complications Following Interpolated Flap Repair: A Single-Center, Retrospective, Cohort Study. *Dermatol Surg Off Publ Am Soc Dermatol Surg Al.* 2023;49:1139-42.
15. Loranger N, Karn E, Anderson J, Groover M, Wang D, Schmults C, et al. Subcutaneous injection of tranexamic acid reduces postoperative bleeding following Mohs

- micrographic surgery: A single-institution cohort study. *J Am Acad Dermatol.* 2024;91:542-4.
16. Tejada VFDS, Zhang L, Zogbi L. Efficacy and safety of topical application of tranexamic acid in patients undergoing reconstructive plastic surgery after excision of facial skin cancers: a randomised clinical trial. *Rev Colégio Bras Cir. s. f.;*51:e20243761.
  17. Ahmed MB, Assami D, Nasrallah D, Saoud Al-Mohannadi F, Al-Maraghi S, Ahmed AB, et al. Tranexamic Acid Application in Facial Aesthetic Surgery: An Umbrella Review. *Aesthetic Surg J Open Forum.* 2024;6:ojae105.
  18. Locketz GD, Lozada KN, Bloom JD. Tranexamic Acid in Aesthetic Facial Plastic Surgery: A Systematic Review of Evidence, Applications, and Outcomes. *Aesthetic Surg J Open Forum.* 2020;2:ojaa029.
  19. AlGhanim K, Al-Youha S, AlWazzan A, AlHamad S. Tranexamic acid in plastic surgery: routes of administration and dosage considerations. *Eur J Plast Surg.* 2021;44:295-305.
  20. Laikhter E, Comer CD, Shiah E, Manstein SM, Bain PA, Lin SJ. A Systematic Review and Meta-Analysis Evaluating the Impact of Tranexamic Acid Administration in Aesthetic Plastic Surgery. *Aesthet Surg J.* 2022;42:548-58.
  21. Elena Scarafoni E. A Systematic Review of Tranexamic Acid in Plastic Surgery: What's New? *Plast Reconstr Surg – Glob Open.* 2021;9:e3172.
  22. Wang S, Yang J, Lin L. Local Application of Tranexamic Acid in Plastic Surgery Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Aesthetic Plast Surg.* 2023;47:1633-43.
  23. Chaichumporn T, Kanokkangsadal P, Sarovath A. Tranexamic Acid Subcutaneously Administered with Epinephrine and Lidocaine in Upper Blepharoplasty: A Randomized Double-Blind Control Trial. *Aesthetic Plast Surg.* 2024;48:3076-81.
  24. Vogt AZ, Kivanany PB, De Niear MA, Vrcek IM, Homer NA. The Effect of Intravenous Tranexamic Acid on Postoperative Ecchymoses after Upper Blepharoplasty. *Plast Reconstr Surg Glob Open.* 2024;12:e6089.
  25. Marous CL, Farhat OJ, Cefalu M, Rothschild MI, Alapati S, Wladis EJ. Effects of Preoperative Intravenous Versus Subcutaneous Tranexamic Acid on Postoperative Periorbital Ecchymosis and Edema Following Upper Eyelid Blepharoplasty: A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Comparative Study. *Ophthal Plast Reconstr Surg.* 2024;40:523-32.
  26. Schroeder RJ, Langsdon PR. Effect of Local Tranexamic Acid on Hemostasis in Rhytidectomy. *Facial Plast Surg Aesthetic Med.* 2020;22:195-9.
  27. Serrano Reyes HM, Ramirez J, Aguilar Villa H, Arbelaez JP, Morrou W, Aniceto M, et al. Tranexamic acid: a simple way to reduce drainage and bleeding in rhytidoplasty. *Eur J Plast Surg.* 2021;44:189-96.
  28. Butz DR, Geldner PD. The Use of Tranexamic Acid in Rhytidectomy Patients. *Plast Reconstr Surg Glob Open.* 2016;4:e716.
  29. Klimczak JA, Abraham M, Hu S, Rouso DE, Perkins S, Hamilton M. Tranexamic Acid in Rhytidectomy: A Split-Face Multi-Institutional Study. *Facial Plast Surg Aesthetic Med.* 2024.
  30. Trimas GE, Frost MDT, Trimas SJ. Tranexamic Acid in Tumescence for Cervicofacial Rhytidectomies. *Plast Reconstr Surg Glob Open.* 2024;12:e5540.
  31. Kochuba AL, Coombs DM, Kwiecien GJ, Sinclair NR, Zins JE. Prospective Study Assessing the Effect of Local Infiltration of Tranexamic Acid on Facelift Bleeding. *Aesthet Surg J.* 2021;41:391-7.
  32. Pou JD, Matabele MN, Robertson KM. Subcutaneous and Topical Tranexamic Acid Use During Rhytidectomy. *The Laryngoscope.* 2024.



33. Couto RA, Charafeddine A, Sinclair NR, Nayak LM, Zins JE. Local Infiltration of Tranexamic Acid With Local Anesthetic Reduces Intraoperative Facelift Bleeding: A Preliminary Report. *Aesthet Surg J*. 2020;40:587-93.
34. Ziegler Rodríguez OR, De la Cruz Ku G, Chávez Díaz M, Ziegler Rodríguez GJ, Ziegler Gutiérrez OE. Safety and Outcomes in Multiplane Facial Rejuvenation with Tranexamic Acid: A Cohort Study. *Plast Reconstr Surg Glob Open*. 2024;12:e5653.
35. Davison SP, Ellor M, Hedicke C, Groth J, Grimmer K. Comparison of Tranexamic Acid Administration Methods in Rhytidectomy: A Prospective, Randomized, Double-blind Study. *Plast Reconstr Surg Glob Open*. 2025;13:e6559.
36. Mergoum AM, Mergoum AS, Larson NJ, Dries DJ, Cook A, Blondeau B, et al. Tranexamic Acid Use in the Surgical Arena: A Narrative Review. *J Surg Res*. 2024;302:208-21.
37. Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. *Health Technol Assess Winch Engl*. 2013;17:1-79.
38. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. *Lancet Lond Engl*. 2017;389:2105-16.
39. Rohrich RJ, Brown S, Brown T, Taub PJ. Role of tranexamic acid (TXA) in plastic and reconstructive surgery: A national perspective. *J Plast Reconstr Aesthet Surg*. 2025;102:373-83.
40. Hourlier H, Fennema P. Tranexamic acid use and risk of thrombosis in regular users of anti-thrombotics undergoing primary total knee arthroplasty: a prospective cohort study. *Blood Transfus Trasfus Sanguie*. 2018;16:44-52.
41. Fischer K, Bodalbhai F, Awudi E, Surani S. Reversing Bleeding Associated With Antiplatelet Use: The Role of Tranexamic Acid. *Cureus*. 2020;12:e10290.
42. Banihashem N, Khorasani M, Vaffai H, Naziri F, Khafri S, Seyfi S. The effect of low-dose tranexamic acid on postoperative blood loss in patients treated with clopidogrel and aspirin. *Casp J Intern Med*. 2019;10:156-61.
43. Yalamanchili S, Talei B, Azizzadeh B, Auersvald A, Frankel AS. Wound Healing Complications With Tranexamic Acid: Not the Silver Bullet After All. *Aesthet Surg J*. 2023;43:1409-15.

**Figure 1. Mechanism of action of tranexamic acid.** **A.** Under normal conditions, tissue plasminogen activator (t-PA) binds to plasminogen, catalyzing its conversion into plasmin, which in turn degrades fibrin, leading to the breakdown of the hemostatic plug. **B.** In the presence of tranexamic acid (TXA), it binds to plasmin, preventing its action on fibrin and promoting hemostasis.



**Table 1.** Studies evaluating tranexamic acid in oncologic dermatologic surgery

Authors & year	Sample size	Study type	Intervention	Main results
Zilinsky et al. <sup>12</sup> , 2016	20	Prospective case-control study	Topical treatment: gauze impregnated with a solution of TXA, epinephrine, and lidocaine vs normal saline applied to the MMS defect across stages.	<ul style="list-style-type: none"> <li>Lower ratio of blood-stain area on gauze (applied to the tumor bed) to surgical defect size in the TXA group (1:1.47) vs saline (1:3.37) (<math>p &lt; 0.001</math>).</li> </ul>
Zilinsky et al. <sup>4</sup> , 2019	127	Double-blind randomized clinical trial	Subcutaneous injection of 2% lidocaine mixed 1:1 with TXA (100 mg/mL) vs the same mixture without TXA diluted 1:1 with saline.	<ul style="list-style-type: none"> <li>Gauze blood-stain/surgical wound size ratio: <ul style="list-style-type: none"> <li>TXA: 1.77 vs placebo: 2.49 (<math>p &lt; 0.001</math>).</li> </ul> </li> <li>-Effect in anticoagulated patients: <ul style="list-style-type: none"> <li>Less bleeding with TXA (-0.83; 95%CI, -1.20 to -0.46; <math>p &lt; 0.001</math>).</li> <li>-Subjective hemostasis assessment: better with TXA overall (<math>p = 0.043</math>) and in the anticoagulated subgroup (<math>p = 0.001</math>).</li> </ul> </li> </ul>
Castillo et al. <sup>10</sup> , 2023	124	Double-blind randomized clinical trial	Dressing with topical TXA 25 mg/mL applied to the post-MMS defect vs dressing with saline.	<ul style="list-style-type: none"> <li>Patients with active bleeding within 48 h post-op: 6 (9.7%) in placebo vs 0 in TXA group (<math>p = 0.028</math>).</li> </ul>
Freeman et al. <sup>14</sup> , 2023	115	Retrospective cohort analysis	Subcutaneous TXA (20–100 mg) ( $n = 21$ ) vs no TXA ( $n = 94$ ) in patients with MMS repaired with interpolated flaps.	<ul style="list-style-type: none"> <li>27 bleeding events in no-TXA vs 1 in TXA group (28.7% vs 4.8%; <math>p &lt; 0.01</math>).</li> </ul>
Loranger et al. <sup>15</sup> , 2024	5,327	Retrospective analysis with historical cohorts	Subcutaneous TXA (2,818 cases) vs no TXA (2,509 cases) in patients with MMS.	<ul style="list-style-type: none"> <li>Reduced bleeding RR by 25% (0.75 [0.57–0.99]) and bleeding requiring medical attention by 51% (0.49 [0.31–0.77]) in the TXA group vs no-TXA.</li> </ul>
Tejada et al. <sup>16</sup> , 2025	54	Double-blind randomized clinical trial	Topical TXA 3% solution (26 cases) vs 0.9% saline (28 cases) applied to the surgical field during facial skin-tumor procedures.	<ul style="list-style-type: none"> <li>Lower bleeding volume with TXA (11.42 mL <math>\pm</math> 6.40) vs placebo (17.60 mL <math>\pm</math> 6.22) (<math>p = 0.001</math>).</li> <li>Lower percentage with ecchymosis in TXA (3.8%) vs placebo (82.1%) (<math>p &lt; 0.001</math>).</li> </ul>

TXA: tranexamic acid; MMS: Mohs micrographic surgery; RCT: randomized clinical trial; CI: confidence interval; IV: intravenous.

**Table 2.** Studies evaluating tranexamic acid in blepharoplasty

Authors & year	Sample size	Study type	Intervention	Main results
Sagiv et al. <sup>6</sup> , 2018	34	Double-blind randomized clinical trial	Each patient: one eyelid received subcutaneous 2% lidocaine with TXA (50 mg/mL) vs the contralateral eyelid with 2% lidocaine without TXA diluted 1:1 with saline.	<ul style="list-style-type: none"> <li>No significant differences in electrocautery use (<math>p = 0.360</math>), total surgical time (<math>p = 0.940</math>), blood loss on dressings (<math>p = 0.602</math>), pain (<math>p = 0.970</math>), or day-1 periocular ecchymosis (2.2 <math>\pm</math> 1.0 with TXA vs 2.3 <math>\pm</math> 1.1 with placebo; <math>p = 0.716</math>).</li> <li>Trend toward less day-7 ecchymosis (1.2 <math>\pm</math> 0.8 vs 1.7 <math>\pm</math> 1.0; <math>p = 0.072</math>) and shorter patient-reported recovery (7.5 <math>\pm</math> 3.0 vs 9.7 <math>\pm</math> 4.6 days; <math>p = 0.11</math>) with TXA.</li> </ul>
Chaichumporn et al. <sup>23</sup> , 2024	15 patients (30 eyelids)	Double-blind randomized clinical trial	Each eyelid randomized to subcutaneous 2% lidocaine with epinephrine (1:100,000) mixed 1:1 with TXA (50 mg/mL) vs the same mixture without TXA diluted 1:1 with saline.	<ul style="list-style-type: none"> <li>Intraoperative blood loss significantly higher with TXA [4.86 (1.83 mL)] vs control [2.53 (1.49 mL)] (<math>p &lt; 0.001</math>).</li> <li>On day 7, no significant differences in ecchymosis area percentage (<math>p = 0.976</math>) or pain score (<math>p = 0.934</math>).</li> </ul>
Marous et al. <sup>25</sup> , 2024	106	Double-blind randomized clinical trial	3 groups: (1) 1 g TXA IV in 100 mL saline 20 min pre-op (2) TXA 50 mg/mL subcutaneous with local anesthesia 2 min pre-incision (3) No TXA.	<ul style="list-style-type: none"> <li>-Less ecchymosis with TXA (IV or subcutaneous) vs control: <ul style="list-style-type: none"> <li>Day 1: 1.31 vs 1.56 vs 2.09 (<math>p = 0.02</math>)</li> <li>Day 7: 0.51 vs 0.66 vs 0.98 (<math>p = 0.04</math>).</li> </ul> </li> <li>No difference between IV and subcutaneous TXA.</li> <li>-Less edema with TXA (IV or subcutaneous) vs control: <ul style="list-style-type: none"> <li>Day 1: 1.59 vs 1.43 vs 1.91 (<math>p = 0.005</math>)</li> <li>Day 7: 0.85 vs 0.60 vs 0.99 (<math>p = 0.04</math>).</li> </ul> </li> </ul>
Paramo et al. <sup>7</sup> , 2024	130 (260 eyelids)	Double-blind randomized clinical trial	Each eyelid randomized to subcutaneous 2% lidocaine with epinephrine (1:100,000) and 0.5% bupivacaine with epinephrine (1:200,000) mixed 1:1 with TXA (50	<ul style="list-style-type: none"> <li>-Less ecchymosis on the TXA side vs control: <ul style="list-style-type: none"> <li>Day 0: 1.39 vs 1.64 (<math>p = 0.001</math>)</li> <li>Day 7: 1.23 vs 1.50 (<math>p &lt; 0.001</math>).</li> </ul> </li> </ul>

Authors & year	Sample size	Study type	Intervention	Main results
			mg/mL) vs the same mixture without TXA.	<ul style="list-style-type: none"> <li>Subjective day-7 assessment: 69% (47/68) reported more ecchymosis on the control side (<math>p &lt; 0.001</math>).</li> </ul>
Vogt et al. <sup>24</sup> , 2024	325	Double-blind randomized clinical trial	1 g TXA IV 10 minutes before the procedure vs none.	<ul style="list-style-type: none"> <li>Less ecchymosis on day 8 in the TXA group: <ul style="list-style-type: none"> <li>No-TXA: <math>5.8 \pm 1.7</math></li> <li>TXA: <math>4.1 \pm 1.6</math> (<math>p &lt; 0.0001</math>).</li> </ul> </li> </ul>

TXA: tranexamic acid; RCT: randomized clinical trial; CI: confidence interval; IV: intravenous.

**Table 3.** Studies evaluating tranexamic acid in facial rhytidectomy (facelift)

Authors & year	Sample size	Study type	Intervention	Main results
Butz et al. <sup>28</sup> , 2016	57	Retrospective case series	TXA-soaked compresses placed under the skin flap while the contralateral side was dissected.	<ul style="list-style-type: none"> <li>1 hematoma (1.7%) required drainage. No skin necrosis, infection, or facial nerve injury.</li> </ul>
Couto et al. <sup>33</sup> , 2019	27	Prospective case series	Local subcutaneous infiltration of a TXA + lidocaine solution (1 mg TXA / 1 mg lidocaine).	<ul style="list-style-type: none"> <li>Marked subjective reduction in bleeding vs prior experience without TXA.</li> <li>Reduced average time to hemostasis: TXA saved ~25–60 minutes of surgical time.</li> </ul>
Schroeder et al. <sup>26</sup> , 2020	76	Retrospective cohort study	100 mg TXA + local anesthetic subcutaneously vs local anesthetic alone.	<ul style="list-style-type: none"> <li>TXA significantly reduced day-1 postoperative drainage (14.8 cc vs 50.4 cc; <math>p &lt; 0.001</math>), enabled faster drain removal (1.2 vs 1.8 days; <math>p = 0.001</math>), increased day-1 drain removal rate (77.3% vs 34.4%; <math>p &lt; 0.001</math>), yielded lower drain volumes (95.5% with <math>&lt; 25</math> cc vs 21.9%; <math>p &lt; 0.001</math>), and reduced intraoperative blood loss (75% with <math>&lt; 50</math> cc vs 25%; <math>p &lt; 0.001</math>).</li> <li>No significant group differences in minor/major hematoma, Nitro-Bid use, or thromboembolic events.</li> </ul>
Serrano Reyes et al. <sup>27</sup> , 2020	30	Prospective cohort study	Intraoperative irrigation with topical TXA 2.5% vs no irrigation.	<ul style="list-style-type: none"> <li>Reduced postoperative drainage in first 24 h with TXA (10 mL vs 35 mL; <math>p = 0.009</math>).</li> <li>Lower complication and hematoma rates in TXA group, not statistically significant.</li> </ul>
Cohen et al. <sup>11</sup> , 2021	44	Double-blind randomized clinical trial	TXA IV 1 g before incision and 4 h after vs IV saline.	<ul style="list-style-type: none"> <li>No statistically significant difference in intraoperative blood loss.</li> <li>Post-op ecchymosis &amp; edema: <ul style="list-style-type: none"> <li>Patient ratings: no significant differences.</li> <li>Surgeon ratings: significant reduction in ecchymosis (<math>1.33 \pm 0.32</math>; <math>p = 0.03</math>) but not edema (<math>1.42 \pm 0.39</math>; <math>p = 0.12</math>–<math>0.26</math>) with TXA.</li> </ul> </li> <li>Serosanguineous collections: 29% in controls vs 4% with TXA (<math>p &lt; 0.01</math>).</li> </ul>
Kochuba et al. <sup>31</sup> , 2021	39	Randomized clinical trial	Subcutaneous TXA 1 mg/mL with local anesthetic vs TXA 2 mg/mL with local anesthetic.	<ul style="list-style-type: none"> <li>Mean time to hemostasis 6.4 min per side in both groups.</li> <li>Low postoperative drainage; drains removed on days 1–2.</li> </ul>
Klimczak et al. <sup>29</sup> , 2024	70	Single-blind randomized clinical trial	One facial side: anesthetic with TXA 1 mg/mL; other side: anesthetic alone.	<ul style="list-style-type: none"> <li>1 week post-op ecchymosis area significantly smaller on the TXA-infiltrated side (<math>p &lt; 0.001</math>).</li> </ul>
Pou et al. <sup>32</sup> , 2024	175	3-arm retrospective comparative study	No TXA vs topical TXA 25 mg/mL vs subcutaneous TXA 5 mg/mL.	<ul style="list-style-type: none"> <li>Both topical and subcutaneous TXA significantly reduced drainage and ecchymosis vs control (<math>p &lt; 0.001</math>).</li> <li>Subcutaneous TXA significantly reduced surgical time (196.13 min) vs topical TXA (212.72 min; <math>p = 0.01</math>) and control (207.90 min; <math>p = 0.037</math>).</li> <li>Lower seromas and blood loss with subcutaneous TXA.</li> <li>Similar rates of hematoma, epidermolysis, and infection across groups.</li> </ul>
Trimas et al. <sup>30</sup> , 2024	74	Double-blind randomized clinical trial	Subcutaneous TXA 250 mg at 1 mg/mL added to local anesthesia vs local anesthesia alone.	<ul style="list-style-type: none"> <li>TXA addition yielded shorter procedure time and lower estimated blood loss, though not statistically significant.</li> </ul>
Ziegler Rodríguez et al. <sup>34</sup> , 2024	100	Retrospective cohort study	Subcutaneous TXA 10 mL/g with local anesthetic + TXA IV 10 mL/g vs local anesthetic with IV saline.	<ul style="list-style-type: none"> <li>TXA group had less intraoperative bleeding (40 mL vs 90 mL; <math>p &lt; 0.05</math>) and shorter surgical time (237 vs 353 min; <math>p &lt; 0.05</math>); no difference in hematoma development, but less ecchymosis (2% vs 36%; <math>p &lt; 0.05</math>), less edema (2% vs 100%; <math>p &lt; 0.05</math>), and shorter time to drain removal (3 vs 6 days; <math>p &lt; 0.05</math>).</li> </ul>

Authors & year	Sample size	Study type	Intervention	Main results
Davison et al. <sup>35</sup> , 2025	60	Double-blind randomized clinical trial	TXA IV 1 g vs TXA 150 mg subcutaneous in facelift patients.	<ul style="list-style-type: none"> <li>• IV TXA enabled faster drain removal (1.16 days) vs local (2.04 days) (p = 0.04).</li> <li>• No significant differences across groups in blood loss, ecchymosis, edema, or overall satisfaction.</li> </ul>

TXA: tranexamic acid; RCT: randomized clinical trial; CI: confidence interval; IV: intravenous.

**Table 4.** Ways to use tranexamic acid in dermatologic surgery

Topical	Soak gauze with one ampoule* of TXA 100 mg/mL.
Subcutaneous/intralesional (mixed in the anesthetic)	Option A: 5 mL TXA 100 mg/mL (one ampoule) + 5 mL 2% lidocaine† (1:1 dilution). Option B: 5 mL 2% mepivacaine (1:1 dilution). Tumescent anesthesia use: 50 mL normal saline + two 10 mL ampoules of 2% mepivacaine + one ampoule of TXA 100 mg/mL + 0.5 mL epinephrine 1 mg/mL.
Subcutaneous/intralesional in the surgical bed	Infiltrate 1 to 5 mL of TXA 100 mg/mL.
Intravenous‡	Infuse 1 g TXA 10–20 minutes before incision.

TXA: tranexamic acid; g: gram; mg: milligram; mL: milliliter.

\*The TXA ampoule is 5 mL at 100 mg/mL.

† Or an ampoule of lidocaine 20 mg/mL + epinephrine 0.0125 mg/mL.

‡ Subcutaneous/intralesional use reflects the authors' experience, whereas the IV route is most frequently described in the literature.

## TRADUCCIÓN DE LA FIGURA

t-PA

Plasminógeno

ATX

Fibrina

Plasmina

Productos de degradación de la fibrina

t-PA

Plasminogen

TXA

Fibrin

Plasmin

Fibrin degradation products